Literature DB >> 25212749

Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol-dependent women: exploratory findings.

George A Kenna1, William H Zywiak2, Robert M Swift3, John E McGeary3, James S Clifford4, Jessica R Shoaff5, Samuel Fricchione5, Michael Brickley5, Kayla Beaucage5, Carolina L Haass-Koffler5, Lorenzo Leggio6.   

Abstract

The purpose of this exploratory study was to examine the interaction of 5-HTTLPR and DRD4 exon III polymorphisms with gender in non-treatment seeking alcohol-dependent (AD) individuals while alternately taking ondansetron and sertraline. Evidence suggests that alcohol dependence may be influenced by a genetic interaction that may be gender-specific with temporal changes making pharmacological treatment with serotonergic drugs complex. The main trial was a within-subject double-blind placebo-controlled human laboratory study with 77 non-treatment-seeking AD individuals randomized (55 completed, 49 complete data) to receive 200 mg/day of sertraline or 0.5 mg/day of ondansetron for 3 weeks followed by an alcohol self-administration experiment (ASAE), then placebo for 3 weeks followed by a second ASAE, then receive the alternate drug, in a counterbalanced order, for 3 weeks followed by a third ASAE. Results for men were not significant. Women with the LL 5-HTTLPR genotype receiving ondansetron and SS/SL 5-HTTLPR genotype receiving sertraline (matched), drank significantly fewer drinks per drinking day (DDD) during the 7 days prior to the first and third ASAEs than women receiving the mismatched medication (i.e., sertraline to LL and ondansetron to SS/SL). In a 3-way interaction, 5-HTTLPR alleles by DRD4 alleles by medications, women with the LL genotype who received ondansetron and had DRD4≥7 exon III repeats drank significantly fewer DDD as did SS/SL women who received sertraline but conversely had DRD4<7 repeats in the 7-day period leading up to the first and third ASAEs. Consistent with these data was a significant reduction of milliliters consumed ad libitum during these same ASAEs. These exploratory findings add possible support to gender and genetic differences among AD individuals in response to serotonergic pharmacotherapies. Future trials should be powerful enough to take into account that endophenotypes and a targeting of serotonergic interactions may be essential to successfully treat alcohol dependence.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  5-HTTLPR; Alcohol; DRD4; Gender; Ondansetron; Sertraline

Mesh:

Substances:

Year:  2014        PMID: 25212749      PMCID: PMC4163011          DOI: 10.1016/j.alcohol.2014.04.005

Source DB:  PubMed          Journal:  Alcohol        ISSN: 0741-8329            Impact factor:   2.405


  53 in total

1.  Commentary on comparison of alcoholism subtypes as moderators of the response to sertraline treatment.

Authors:  John D Roache
Journal:  Alcohol Clin Exp Res       Date:  2012-03-20       Impact factor: 3.455

2.  Chronic alcohol effects on anterior pituitary and ovarian hormones in healthy women.

Authors:  J H Mendelson; N K Mello
Journal:  J Pharmacol Exp Ther       Date:  1988-05       Impact factor: 4.030

Review 3.  Subjective responses to alcohol consumption as endophenotypes: advancing behavioral genetics in etiological and treatment models of alcoholism.

Authors:  Lara A Ray; James Mackillop; Peter M Monti
Journal:  Subst Use Misuse       Date:  2010-09       Impact factor: 2.164

4.  Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder.

Authors:  Xian-Zhang Hu; Robert H Lipsky; Guanshan Zhu; Longina A Akhtar; Julie Taubman; Benjamin D Greenberg; Ke Xu; Paul D Arnold; Margaret A Richter; James L Kennedy; Dennis L Murphy; David Goldman
Journal:  Am J Hum Genet       Date:  2006-03-28       Impact factor: 11.025

5.  Pharmacological treatment of alcohol dependence: a review of the evidence.

Authors:  J C Garbutt; S L West; T S Carey; K N Lohr; F T Crews
Journal:  JAMA       Date:  1999-04-14       Impact factor: 56.272

6.  An expanded evaluation of the relationship of four alleles to the level of response to alcohol and the alcoholism risk.

Authors:  Xianzhang Hu; Gabor Oroszi; Jeffrey Chun; Tom L Smith; David Goldman; Marc A Schuckit
Journal:  Alcohol Clin Exp Res       Date:  2005-01       Impact factor: 3.455

7.  Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction.

Authors:  Kent E Hutchison; Angela Wooden; Robert M Swift; Andrew Smolen; John McGeary; Lawrence Adler; Lyndee Paris
Journal:  Neuropsychopharmacology       Date:  2003-10       Impact factor: 7.853

8.  Gender differences in response to sertraline pharmacotherapy in Type A alcohol dependence.

Authors:  Helen M Pettinati; William Dundon; Craig Lipkin
Journal:  Am J Addict       Date:  2004 May-Jun

9.  Modulation of midbrain dopamine neurotransmission by serotonin, a versatile interaction between neurotransmitters and significance for antipsychotic drug action.

Authors:  J E Olijslagers; T R Werkman; A C McCreary; C G Kruse; W J Wadman
Journal:  Curr Neuropharmacol       Date:  2006-01       Impact factor: 7.363

Review 10.  The DRD4 exon 3 VNTR polymorphism and addiction-related phenotypes: a review.

Authors:  John McGeary
Journal:  Pharmacol Biochem Behav       Date:  2009-03-29       Impact factor: 3.533

View more
  8 in total

Review 1.  Variation in the Serotonin Transporter Gene and Alcoholism: Risk and Response to Pharmacotherapy.

Authors:  Miles D Thompson; George A Kenna
Journal:  Alcohol Alcohol       Date:  2015-08-26       Impact factor: 2.826

Review 2.  Pharmacogenetics of alcohol use disorder treatments: an update.

Authors:  Emily E Hartwell; Henry R Kranzler
Journal:  Expert Opin Drug Metab Toxicol       Date:  2019-06-11       Impact factor: 4.481

3.  An inpatient human laboratory study assessing the safety and tolerability, pharmacokinetics, and biobehavioral effect of GET 73 when co-administered with alcohol in individuals with alcohol use disorder.

Authors:  Carolina L Haass-Koffler; Roberta Perciballi; Molly Magill; Antonella Loche; Roberto Cacciaglia; Lorenzo Leggio; Robert M Swift
Journal:  Psychopharmacology (Berl)       Date:  2021-11-03       Impact factor: 4.530

4.  Pharmacotherapies and personalized medicine for alcohol use disorder: a review.

Authors:  Falk W Lohoff
Journal:  Pharmacogenomics       Date:  2020-08-18       Impact factor: 2.533

5.  Parental Problem Drinking and Maladaptive Personality Features in Children: The Role of Marital Conflict.

Authors:  Peggy S Keller; Thomas A Widiger; Mona El-Sheikh
Journal:  Child Psychiatry Hum Dev       Date:  2022-03-12

6.  Parsing out the role of dopamine D4 receptor gene (DRD4) on alcohol-related phenotypes: A meta-analysis and systematic review.

Authors:  Allison M Daurio; Sara L Deschaine; Amirhossein Modabbernia; Lorenzo Leggio
Journal:  Addict Biol       Date:  2019-05-31       Impact factor: 4.093

Review 7.  Consideration of sex and gender differences in addiction medication response.

Authors:  Sherry A McKee; Aimee L McRae-Clark
Journal:  Biol Sex Differ       Date:  2022-06-27       Impact factor: 8.811

Review 8.  Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review.

Authors:  Pascal Valentin Fischler; Michael Soyka; Erich Seifritz; Jochen Mutschler
Journal:  Front Pharmacol       Date:  2022-10-03       Impact factor: 5.988

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.